Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
Curanex Pharmaceuticals is broadening its drug development pipeline to include cancer cachexia, a serious and unmet supportive care condition in oncology patients. This expansion complements its existing focus on inflammatory and metabolic diseases, marking a strategic evolution toward a broader therapeutics company. The global market for cancer ca…